RightIssue

[ASB] Rights Issue on 03-Oct-2022

Announcement Date: 13-Sep-2022
Related Stock:
ASB
ADVANCE SYNERGY BHD
Share Registrar:
ASB
ADVANCE SYNERGY BHD
Amount

2.0000 : 1.0000

  • Ex Date
    03-Oct-2022
  • Entitlement Date
    04-Oct-2022
Description
RENOUNCEABLE RIGHTS ISSUE OF UP TO 1,858,389,886 NEW ORDINARY SHARES IN ADVANCE SYNERGY BERHAD ("ASB") ("RIGHTS SHARES") AT AN ISSUE PRICE OF RM0.05 PER RIGHTS SHARE ON THE BASIS OF TWO (2) RIGHTS SHARES FOR EVERY ONE (1) EXISTING ORDINARY SHARE IN ASB HELD AS AT 5:00 P.M. ON TUESDAY, 4 OCTOBER 2022 ("RIGHTS ISSUE")

About ADVANCE SYNERGY BHD
Advance Synergy Bhd is an investment holding company. Its segments include Investment Holding, which provides corporate and financial support to the group; Property Development engages in the development of residential and commercial properties; Hotels and Resorts operates and manages hotels and resorts; Information and Communications Technology segment is engaged in the design and development of telecommunications software applications and systems; Travel and Tours segment is involved in the money services business and provision of travel-related services; Others segment is engaged in the manufacturing and marketing of builder hardware products. The company operates mainly in Malaysia, Singapore, Africa and the Middle East, Europe and Australia.

How to be entitled
To be entitled for any of the above, you need to purchase the shares one trading day before the ex-Date. You will not be entitled for the above if you purchase the shares on or after the ex-Date.

On ex-Date, the price will be adjusted to reflect the theoretical market price of the stock after the entitlement. You can sell the shares on / after ex-Date and still be entitled to the corporate exercise. The key is to purchase the shares before ex-Date.
How to subscribe
Shareholders that fulfill the requirement above will need to fill in and submit the right subscription form to the share registrar:

Market Buzz
Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment